Ambrx

Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx's technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties.

In August 2016, the company secured a $45 million round of financing led by Apricot Capital and Northeast Securities Prosperity Healthcare Fund.

The same month, it received approval for its Investigational New Drug (IND) from the Food and Drug Administration to start clinical trials in the USA for its novel HER2 targeting antibody drug conjugate(ADC) ARX788, which is currently in Phase I trials in Australia and New Zealand.

Latest Ambrx News & Features